

NOTE: This order is nonprecedential.

**United States Court of Appeals  
for the Federal Circuit**

---

**REGENERON PHARMACEUTICALS, INC.,**  
*Plaintiff-Appellant*

v.

**MYLAN PHARMACEUTICALS INC., BIOCON  
BIOLOGICS INC.,**  
*Defendants-Cross-Appellants*

**AMGEN USA, INC.,**  
*Defendant*

---

2024-1402, 2024-1405

---

Appeals from the United States District Court for the Northern District of West Virginia in No. 1:22-cv-00061-TSK-JPM, Chief Judge Thomas S. Kleeh.

---

Before CHEN, LINN, and HUGHES, *Circuit Judges*.

PER CURIAM.

**O R D E R**

Following this court's February 22, 2024 show cause order, the parties agree that the court lacks jurisdiction over both the appeal and cross-appeal from the district court's December 27, 2023 decision resolving fewer than all

2

REGENERON PHARMACEUTICALS, INC. v. MYLAN  
PHARMACEUTICALS INC.

claims at issue. Under the circumstances, we agree and conclude that dismissal is appropriate.

Accordingly,

IT IS ORDERED THAT:

(1) Appeal Nos. 2024-1402 and 2024-1405 are dismissed.

(2) Each party shall bear its own costs.

FOR THE COURT



Jarrett B. Perlow  
Clerk of Court

April 12, 2024  
Date

ISSUED AS A MANDATE: April 12, 2024